



SOUTH CENTRAL RAILWAY

General Manager's Office,
Secunderabad – 500 025.

Date: 30.04.2021.

No: SCR-HQ0GMO(SOP)/1/2020

MEMORANDUM

Sub: Correction slip No: 10 to the Model SOP 2018 – Inclusion of item No: 7 (e) to Part 'B' - Medical Matters of Model SOP 2018.

<><><>

The following new item is included for Local Purchase of Drugs & related items for treatment of COVID – 19 as item No: 7 (e) to Part 'B' - Medical Matters of Model SOP 2018:

Sl. No.	Nature of Powers	PCMD, other HQ officers & MD (Zonal Hospital)	DRM,CWM (SAG) & SAG Officers in independent charge of Divisional/ Sub-divisional/ Workshop/PU Hospitals	SG/JA Grade officers of Divisional/ Sub-divisional/ Workshop/ Hospital Incharges	Sr Scale & Asst. Scale officers	REMARKS
7	(e) <u>Local Purchase of Drugs & related items for treatment of COVID – 19.</u> Emergency purchase of drugs & related items in reasonable quantity to tide over the emergency, which are in short supply or out of stock, for Covid-19 treatment	<u>PCMD</u> Up to Rs. 3 Lakhs in each case <u>MD (Zonal Hospital)</u> Up to Rs. 2 Lakhs in each case	<u>CMS/CMO (In SAG)</u> Up to Rs. 1 Lakh In each case	-	-	1. Finance concurrence is not necessary. 2. Powers are restricted to procurement of only those items as is listed in Annexure 'A' . (To be treated as Annexure 'A' to Part 'B' of MSOP, 2018). 3. Powers to be exercised up to total ceiling of Rs.3 crores. PCMD will advise the distribution thereof for MD(Zonal Hospital) and each CMS/CMO. Enhancement of this ceiling will require PFA's concurrence and GM's sanction. 4. These powers are valid up to 30-06-2021 (Sunset Clause). For any further extension beyond 30-06-2021 if justified, PCMD shall process for fresh concurrence of PFA. 5. Each Authority [PCMD/MD(CH)/CMS(SAG)/CMO(SAG)] shall utilize these powers judiciously for purchase on COVID account only bare minimum quantity to tide over emergencies duly taking into account stock, demand at relevant time and POs released and likely supplies against these POs. Due procedure as applicable for emergency purchases shall be followed. 6. Sanctioning Authority shall ensure rate reasonability on each occasion by consulting latest State / Central Government

	through IREPS / Firms registered in PCMD's office.					<p>orders (GO/OM) on pricing of these Drugs / Related items if any as well as recent purchase records (whether issued through Stores or locally) and prevailing market conditions.</p> <p>7. Sanction memorandum shall be issued for each case and cumulative record of these purchases and balance value shall be recorded in a separate / distinct register. Weekly report of sanctions accorded, quantity received /due and balance amount remaining will be sent to PCMD's office by each delegated authority. PCMD's office shall include the sanctions accorded by PCMD under his powers and send copies of consolidated position to PFA's office. Copies of Sanction Memorandum shall also be docketed to Bill Paying Accounts Office for record and to watch progressive expenditure.</p> <p>8. Exercise of these powers is subject to clear availability /certification of funds within the budget allotment under relevant head of account.</p> <p>9. PAC certificate as applicable shall be obtained from Competent Authority before procurement of proprietary drugs, if any.</p> <p>10. Quantity procured under these powers shall be duly reckoned for regulating/reducing AMI/Supplementary Indent quantity.</p> <p>11. These powers will stand frozen once the ceiling limit (as per (3) above) and /or validity (as per (4) above) lapses unless enhanced/extended by Competent Authority as provided herein.</p> <p>12. These powers shall be in addition to the powers delegated under Item 7(a), 7(b), 7(b)(i), 7(c), and 7(d). However, overlapping /duplication in procurement shall be avoided.</p> <p>13. Any extant orders of Railway Board on Local Purchase of Drugs and other equipment as applicable shall be adhered to.</p> <p>14. Procurement through IREPS or Firms registered at PCMD's office will be decided by Sanctioning authority based on quantity / value of each case.</p> <p>[Authority: PFA's concurrence vide letter no. AFX/SOP/Part B dt: 30.04.2021].</p>
--	--	--	--	--	--	--

This issues with concurrence of Finance and approval of General Manager

To : All concerned

K MUTYALA NAIDU Digitally signed by
K MUTYALA NAIDU
Date: 2021.04.30
20:29:06 +05'30'

DY. GENERAL MANAGER (G)

Annexure 'A'
(Part 'B', MSOP-2018)
[Refer Item 7 (e)]

Sl. No.	PH No.	Name of the Drug / Item
1.	526091/526095	PPE KIT / PPE KIT - I
2.	526025/ 526024	N-95 MASKS/N95 MASKS WITHOUT EXPIRATORY VALVE OR ALTERNATIVE AS APPROVED WITH RELEVANT PH NUMBER.
3.	47079/80/81/82	SURGICAL GLOVES SIZE 6; 6.5; 7.0; 7.5
4.	58250	REMDESIVIR 100 MG INJ OR ALTERNATIVE AS APPROVED WITH RELEVANT PH NUMBER.
5.	58032	FAVAPIRAVIR 200 MG TAB OR ALTERNATIVE AS APPROVED WITH RELEVANT PH NUMBER.
6.	7005/7011	ENOXAPARIN 40 MG/0.4 ML, 60 MG/0.6 ML PFS OR ALTERNATIVE AS APPROVED WITH RELEVANT PH NUMBER.
7.	335025	REAGENT FOR THE QUANTITATIVE ESTIMATION OF FERRITIN IN PATIENT SAMPLES IN VIDAS EQUIPMENT, 60 TESTS PER KIT
8.	326087	REAGENT FOR QUANTITATIVE ESTIMATION OF D DIMER IN PATIENT SAMPLES IN ROCHE COBAS C 311 EQUIPMENT
9.	326082	REAGENT FOR QUANTITATIVE ESTIMATION OF C REACTIVE PROTEIN IN PATIENTS SAMPLES FOR USE IN ROCHE COBAS C 311 EQUIPMENT
10.	40694	L D H KIT FOR ERBA – 7.5 X 6.5 ML
11.	326187	IMMUNOCHROMATOGRAPHIC TEST FOR DETECTION OF COVID 19 ANTIGEN (RAPID ANTIGEN TEST)

K
MUTYALA
NAIDU

Digitally signed
by K MUTYALA
NAIDU
Date: 2021.04.30
20:29:38 +05'30'

